5,823 reports of this reaction
1.9% of all ADALIMUMAB ADAZ reports
#4 most reported adverse reaction
RHEUMATOID ARTHRITIS is the #4 most commonly reported adverse reaction for ADALIMUMAB ADAZ, manufactured by Cordavis Limited. There are 5,823 FDA adverse event reports linking ADALIMUMAB ADAZ to RHEUMATOID ARTHRITIS. This represents approximately 1.9% of all 305,491 adverse event reports for this drug.
Patients taking ADALIMUMAB ADAZ who experience rheumatoid arthritis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RHEUMATOID ARTHRITIS is a less commonly reported adverse event for ADALIMUMAB ADAZ, but still significant enough to appear in the safety profile.
In addition to rheumatoid arthritis, the following adverse reactions have been reported for ADALIMUMAB ADAZ:
The following drugs have also been linked to rheumatoid arthritis in FDA adverse event reports:
RHEUMATOID ARTHRITIS has been reported as an adverse event in 5,823 FDA reports for ADALIMUMAB ADAZ. This does not prove causation, but indicates an association observed in post-market surveillance data.
RHEUMATOID ARTHRITIS accounts for approximately 1.9% of all adverse event reports for ADALIMUMAB ADAZ, making it a notable side effect.
If you experience rheumatoid arthritis while taking ADALIMUMAB ADAZ, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.